Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Transepithelial transport across the blood–testis barrier

Miller SR, Cherrington NJ.

Reproduction. 2018 Sep 27. pii: REP-18-0338. doi: 10.1530/REP-18-0338. [Epub ahead of print]

PMID:
30328342
2.

Gene-by-Environment Interaction of Bcrp-/- and Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition.

Toth EL, Li H, Dzierlenga AL, Clarke JD, Vildhede A, Goedken M, Cherrington NJ.

Drug Metab Dispos. 2018 Nov;46(11):1478-1486. doi: 10.1124/dmd.118.082081. Epub 2018 Aug 30.

PMID:
30166404
3.

Alcohol Metabolism in the Progression of Human Nonalcoholic Steatohepatitis.

Li H, Toth E, Cherrington NJ.

Toxicol Sci. 2018 Aug 1;164(2):428-438. doi: 10.1093/toxsci/kfy106.

PMID:
29718361
4.

Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis.

Dzierlenga AL, Cherrington NJ.

J Biochem Mol Toxicol. 2018 Mar;32(3):e22035. doi: 10.1002/jbt.22035. Epub 2018 Jan 17.

PMID:
29341352
5.

Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH.

Li H, Toth E, Cherrington NJ.

Toxicol Sci. 2018 Jan 1;161(1):23-33. doi: 10.1093/toxsci/kfx253.

PMID:
29145614
6.

Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.

Li H, Canet MJ, Clarke JD, Billheimer D, Xanthakos SA, Lavine JE, Erickson RP, Cherrington NJ.

Drug Metab Dispos. 2017 Dec;45(12):1317-1325. doi: 10.1124/dmd.117.077644. Epub 2017 Oct 6.

PMID:
28986475
7.

Dysregulated expression of proteins associated with ER stress, autophagy and apoptosis in tissues from nonalcoholic fatty liver disease.

Lee S, Kim S, Hwang S, Cherrington NJ, Ryu DY.

Oncotarget. 2017 Jun 28;8(38):63370-63381. doi: 10.18632/oncotarget.18812. eCollection 2017 Sep 8.

8.

Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model.

Han J, Dzierlenga AL, Lu Z, Billheimer DD, Torabzadeh E, Lake AD, Li H, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lehman-McKeeman LD, Cherrington NJ.

Obesity (Silver Spring). 2017 Jun;25(6):1069-1076. doi: 10.1002/oby.21855. Epub 2017 Apr 28.

9.

Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO).

Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, Jeong H, Morgan ET, Turnbaugh PJ, Klaassen CD, Bhatt AP, Redinbo MR, Hao P, Waxman DJ, Wang L, Zhong XB.

Acta Pharm Sin B. 2017 Mar;7(2):241-248. doi: 10.1016/j.apsb.2016.12.006. Epub 2017 Feb 1.

10.

Localization of nucleoside transporters in rat epididymis.

Klein DM, Harding MC, Crowther MK, Cherrington NJ.

J Biochem Mol Toxicol. 2017 Aug;31(8). doi: 10.1002/jbt.21911. Epub 2017 Mar 21.

PMID:
28322028
11.

Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.

Clarke JD, Novak P, Lake AD, Hardwick RN, Cherrington NJ.

Liver Int. 2017 Jul;37(7):1074-1081. doi: 10.1111/liv.13362. Epub 2017 Feb 7.

12.

Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis.

Lake AD, Chaput AL, Novak P, Cherrington NJ, Smith CL.

Biochem Pharmacol. 2016 Dec 15;122:62-71. doi: 10.1016/j.bcp.2016.11.006. Epub 2016 Nov 9.

13.

In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice.

Li H, Clarke JD, Dzierlenga AL, Bear J, Goedken MJ, Cherrington NJ.

J Biochem Mol Toxicol. 2017 Feb;31(2). doi: 10.1002/jbt.21840. Epub 2016 Oct 6.

14.

Nonalcoholic Steatohepatitis Modulates Membrane Protein Retrieval and Insertion Processes.

Dzierlenga AL, Clarke JD, Cherrington NJ.

Drug Metab Dispos. 2016 Nov;44(11):1799-1807. Epub 2016 Sep 7.

15.

Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.

Laho T, Clarke JD, Dzierlenga AL, Li H, Klein DM, Goedken M, Micuda S, Cherrington NJ.

Biochem Pharmacol. 2016 Sep 1;115:144-51. doi: 10.1016/j.bcp.2016.07.001. Epub 2016 Jul 2.

16.

Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis.

Dzierlenga AL, Clarke JD, Klein DM, Anumol T, Snyder SA, Li H, Cherrington NJ.

J Pharmacol Exp Ther. 2016 Aug;358(2):246-53. doi: 10.1124/jpet.116.234310. Epub 2016 May 27.

17.

Altered Hepatic Transport by Fetal Arsenite Exposure in Diet-Induced Fatty Liver Disease.

Ditzel EJ, Li H, Foy CE, Perrera AB, Parker P, Renquist BJ, Cherrington NJ, Camenisch TD.

J Biochem Mol Toxicol. 2016 Jul;30(7):321-30. doi: 10.1002/jbt.21796. Epub 2016 Feb 18.

18.

Hepatic Transporter Expression in Metabolic Syndrome: Phenotype, Serum Metabolic Hormones, and Transcription Factor Expression.

Donepudi AC, Cheng Q, Lu ZJ, Cherrington NJ, Slitt AL.

Drug Metab Dispos. 2016 Apr;44(4):518-26. doi: 10.1124/dmd.115.066779. Epub 2016 Feb 4.

19.

Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.

Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ.

Diabetes. 2015 Sep;64(9):3305-13. doi: 10.2337/db14-1947. Epub 2015 May 27.

20.

Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.

Clarke JD, Cherrington NJ.

Pharmacol Ther. 2015 Jul;151:99-106. doi: 10.1016/j.pharmthera.2015.03.005. Epub 2015 Mar 21. Review.

21.

Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.

Canet MJ, Merrell MD, Hardwick RN, Bataille AM, Campion SN, Ferreira DW, Xanthakos SA, Manautou JE, A-Kader HH, Erickson RP, Cherrington NJ.

Drug Metab Dispos. 2015 Jun;43(6):829-35. doi: 10.1124/dmd.114.062703. Epub 2015 Mar 18.

22.

Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ.

Amino Acids. 2015 Mar;47(3):603-15. doi: 10.1007/s00726-014-1894-9. Epub 2014 Dec 23.

23.

Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.

Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, Cherrington NJ.

J Pharmacol Exp Ther. 2015 Mar;352(3):462-70. doi: 10.1124/jpet.114.220764. Epub 2014 Dec 15.

24.

Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ.

Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.

25.

Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene.

Canet MJ, Merrell MD, Harder BG, Maher JM, Wu T, Lickteig AJ, Jackson JP, Zhang DD, Yamamoto M, Cherrington NJ.

Drug Metab Dispos. 2015 Jan;43(1):93-9. doi: 10.1124/dmd.114.060103. Epub 2014 Oct 27.

26.

Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat.

Kyriakides M, Hardwick RN, Jin Z, Goedken MJ, Holmes E, Cherrington NJ, Coen M.

Toxicol Sci. 2014 Nov;142(1):105-16. doi: 10.1093/toxsci/kfu160. Epub 2014 Aug 21.

27.

Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.

Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ.

Toxicol Sci. 2014 Nov;142(1):45-55. doi: 10.1093/toxsci/kfu156. Epub 2014 Jul 31.

28.

Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Canet MJ, Cherrington NJ.

Expert Opin Drug Metab Toxicol. 2014 Sep;10(9):1209-19. doi: 10.1517/17425255.2014.936378. Epub 2014 Jul 3. Review.

29.

Xenobiotic transporter expression along the male genital tract.

Klein DM, Wright SH, Cherrington NJ.

Reprod Toxicol. 2014 Aug;47:1-8. doi: 10.1016/j.reprotox.2014.04.009. Epub 2014 May 9.

30.

Organic and inorganic transporters of the testis: A review.

Klein DM, Cherrington NJ.

Spermatogenesis. 2015 Jan 7;4(2):e979653. eCollection 2014 May-Aug. Review.

31.

Synergistic interaction between genetics and disease on pravastatin disposition.

Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ.

J Hepatol. 2014 Jul;61(1):139-47. doi: 10.1016/j.jhep.2014.02.021. Epub 2014 Mar 5.

32.

Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ.

J Pharmacol Exp Ther. 2014 Mar;348(3):452-8. doi: 10.1124/jpet.113.211284. Epub 2014 Jan 8.

33.

Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ.

Drug Metab Dispos. 2014 Apr;42(4):586-95. doi: 10.1124/dmd.113.055996. Epub 2014 Jan 2.

34.

Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice.

Merrell MD, Nyagode BA, Clarke JD, Cherrington NJ, Morgan ET.

Drug Metab Dispos. 2014 Apr;42(4):596-602. doi: 10.1124/dmd.113.055525. Epub 2013 Dec 30.

35.

Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis.

Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ.

J Appl Toxicol. 2014 Jun;34(6):726-32. doi: 10.1002/jat.2960. Epub 2013 Nov 12.

36.

Localization of multidrug resistance-associated proteins along the blood-testis barrier in rat, macaque, and human testis.

Klein DM, Wright SH, Cherrington NJ.

Drug Metab Dispos. 2014 Jan;42(1):89-93. doi: 10.1124/dmd.113.054577. Epub 2013 Oct 15.

37.

The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Hardwick RN, Flores-Keown B, Zhao F, Klimecki WT, Cherrington NJ.

Toxicol Sci. 2014 Jan;137(1):26-35. doi: 10.1093/toxsci/kft230. Epub 2013 Oct 4.

38.

Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.

Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ.

Dig Dis Sci. 2014 Feb;59(2):365-74. doi: 10.1007/s10620-013-2873-9. Epub 2013 Sep 19.

39.
40.

Downregulation of sulfotransferase expression and activity in diseased human livers.

Yalcin EB, More V, Neira KL, Lu ZJ, Cherrington NJ, Slitt AL, King RS.

Drug Metab Dispos. 2013 Sep;41(9):1642-50. doi: 10.1124/dmd.113.050930. Epub 2013 Jun 17.

41.

Basolateral uptake of nucleosides by Sertoli cells is mediated primarily by equilibrative nucleoside transporter 1.

Klein DM, Evans KK, Hardwick RN, Dantzler WH, Wright SH, Cherrington NJ.

J Pharmacol Exp Ther. 2013 Jul;346(1):121-9. doi: 10.1124/jpet.113.203265. Epub 2013 May 2.

42.

Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver.

More VR, Cheng Q, Donepudi AC, Buckley DB, Lu ZJ, Cherrington NJ, Slitt AL.

Drug Metab Dispos. 2013 May;41(5):1148-55. doi: 10.1124/dmd.112.049676. Epub 2013 Mar 5.

43.

Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ.

Toxicol Appl Pharmacol. 2013 Apr 15;268(2):132-40. doi: 10.1016/j.taap.2013.01.022. Epub 2013 Feb 4.

44.

Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, Cherrington NJ.

Drug Metab Dispos. 2013 Mar;41(3):554-61. doi: 10.1124/dmd.112.048439. Epub 2012 Dec 7.

45.

The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis.

Cherrington NJ, Estrada TE, Frisk HA, Canet MJ, Hardwick RN, Dvorak B, Lux K, Halpern MD.

Am J Physiol Gastrointest Liver Physiol. 2013 Jan 1;304(1):G48-56. doi: 10.1152/ajpgi.00317.2012. Epub 2012 Nov 1.

46.

Altered arsenic disposition in experimental nonalcoholic fatty liver disease.

Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, Cherrington NJ.

Drug Metab Dispos. 2012 Sep;40(9):1817-24. doi: 10.1124/dmd.112.046177. Epub 2012 Jun 14.

47.

Measuring altered disposition of xenobiotics in experimental models of liver disease.

Hardwick RN, Cherrington NJ.

Curr Protoc Toxicol. 2012 May;Chapter 23:Unit 23.1.. doi: 10.1002/0471140856.tx2301s52.

PMID:
22549269
48.

Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.

Clarke JD, Cherrington NJ.

Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):349-60. doi: 10.1517/17425255.2012.656087. Epub 2012 Jan 27. Review.

49.

Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.

Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ.

Drug Metab Dispos. 2012 Mar;40(3):450-60. doi: 10.1124/dmd.111.041095. Epub 2011 Nov 23.

50.

Genetic variation in the mouse model of Niemann Pick C1 affects female, as well as male, adiposity, and hepatic bile transporters but has indeterminate effects on caveolae.

Jelinek DA, Maghsoodi B, Borbon IA, Hardwick RN, Cherrington NJ, Erickson RP.

Gene. 2012 Jan 10;491(2):128-34. doi: 10.1016/j.gene.2011.10.010. Epub 2011 Oct 14.

Supplemental Content

Loading ...
Support Center